AR129934A1 - Compuestos macrocíclicos para el tratamiento de cáncer - Google Patents
Compuestos macrocíclicos para el tratamiento de cáncerInfo
- Publication number
- AR129934A1 AR129934A1 ARP230101857A ARP230101857A AR129934A1 AR 129934 A1 AR129934 A1 AR 129934A1 AR P230101857 A ARP230101857 A AR P230101857A AR P230101857 A ARP230101857 A AR P230101857A AR 129934 A1 AR129934 A1 AR 129934A1
- Authority
- AR
- Argentina
- Prior art keywords
- cancer
- 6alkyl
- compound according
- 6haloalkyl
- morpholinyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1), en donde R¹ es un resto de fórmula (2), 3-oxo-5,6,8,8a-tetrahidro-1H-imidazo[5,1-c][1,4]oxazinilo o (alquil C₁₋₆)oxoimidazolidinilo; en donde R⁸ es alquil C₁₋₆; R⁹ es ((alquil C₁₋₆)₂amino)azetidinilo, alquilpiperazinil C₁₋₆, haloazetidinilo, haloalquilamino C₁₋₆, haloalquilaminoazetidinil C₁₋₆, haloalquilpiperazinil C₁₋₆, hidroxi(alquil C₁₋₆)piperidinilo o morfolinilo; R² es alquil C₁₋₆; R³ es H o halógeno; R⁴ es H o halógeno; R⁵ es alquil C₁₋₆ o haloalquil C₁₋₆; R⁶ es alcoxi C₁₋₆alquil C₁₋₆; R⁷ es morfolinilo, (haloalquil C₁₋₆)piperazinilo o alquilpiperazinil C₁₋₆; A¹ es tiazolileno; A² es alquilen C₁₋₆; siempre que R³ y R⁴ no sean H en simultáneo; o una sal farmacéuticamente aceptable de este. Reivindicación 25: El uso de un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 20 para tratar una enfermedad relacionada con la proteína KRAS G12C, G12D y G12V. Reivindicación 26: El uso de un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 20 para inhibir la interacción de RAS con efectores corriente abajo, en donde los efectores corriente abajo son RAF y PI3K. Reivindicación 27: El uso de un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 20 para inhibir la señalización de MAPK y PI3K oncogénicas en propagación. Reivindicación 28: El uso de un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 20 para el tratamiento o profilaxis de tipos de cáncer causados por mutación de KRAS, en donde el cáncer se selecciona de cáncer pancreático, cáncer colorrectal, cáncer de pulmón, cáncer de esófago, cáncer de vesícula biliar, cáncer de ovario melanoma y cáncer endométrico. Reivindicación 29: El uso de un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 20 para el tratamiento o profilaxis de tipos de cáncer causados por mutación de KRAS, en donde el cáncer se selecciona de adenocarcinoma pancreático, cáncer colorrectal y cáncer de pulmón no microcítico.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022106792 | 2022-07-20 | ||
| CN2022128979 | 2022-11-01 | ||
| CN2023070766 | 2023-01-05 | ||
| CN2023087631 | 2023-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR129934A1 true AR129934A1 (es) | 2024-10-16 |
Family
ID=87514141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230101857A AR129934A1 (es) | 2022-07-20 | 2023-07-14 | Compuestos macrocíclicos para el tratamiento de cáncer |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20250268894A1 (es) |
| EP (1) | EP4558507B1 (es) |
| JP (1) | JP2025525565A (es) |
| KR (1) | KR20250034953A (es) |
| CN (1) | CN119585284A (es) |
| AR (1) | AR129934A1 (es) |
| AU (1) | AU2023311244A1 (es) |
| CA (1) | CA3261063A1 (es) |
| CL (1) | CL2025000081A1 (es) |
| CO (1) | CO2025001184A2 (es) |
| CR (1) | CR20250017A (es) |
| IL (1) | IL316706A (es) |
| MA (1) | MA71551A (es) |
| MX (1) | MX2025000642A (es) |
| PE (1) | PE20250850A1 (es) |
| TW (1) | TWI860785B (es) |
| WO (1) | WO2024017859A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| KR20250085767A (ko) | 2022-09-29 | 2025-06-12 | 광조우 조요 파마테크 컴퍼니 리미티드 | 거대고리 유도체 및 이의 적용 |
| CN120813588A (zh) | 2023-02-14 | 2025-10-17 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的三环化合物 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CR20250420A (es) | 2023-04-07 | 2025-11-20 | Revolution Medicines Inc | Inhibidores macrocíclicos de ras |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015740A1 (en) * | 2024-07-11 | 2026-01-15 | Treeline Biosciences, Inc. | Macrocyclic ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220218852A1 (en) | 2019-04-18 | 2022-07-14 | Provincial Health Services Authority | Novel radiolabelled cxcr4-targeting compounds for diagnosis and therapy |
| AU2020377925A1 (en) * | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| CA3194067A1 (en) * | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
-
2023
- 2023-07-14 AR ARP230101857A patent/AR129934A1/es unknown
- 2023-07-18 KR KR1020257001146A patent/KR20250034953A/ko active Pending
- 2023-07-18 CN CN202380054201.7A patent/CN119585284A/zh active Pending
- 2023-07-18 EP EP23748009.0A patent/EP4558507B1/en active Active
- 2023-07-18 JP JP2025502539A patent/JP2025525565A/ja active Pending
- 2023-07-18 PE PE2025000193A patent/PE20250850A1/es unknown
- 2023-07-18 IL IL316706A patent/IL316706A/en unknown
- 2023-07-18 AU AU2023311244A patent/AU2023311244A1/en active Pending
- 2023-07-18 WO PCT/EP2023/069851 patent/WO2024017859A1/en not_active Ceased
- 2023-07-18 CA CA3261063A patent/CA3261063A1/en active Pending
- 2023-07-18 CR CR20250017A patent/CR20250017A/es unknown
- 2023-07-18 MA MA71551A patent/MA71551A/fr unknown
- 2023-07-19 TW TW112126951A patent/TWI860785B/zh active
-
2025
- 2025-01-13 CL CL2025000081A patent/CL2025000081A1/es unknown
- 2025-01-16 US US19/025,165 patent/US20250268894A1/en active Pending
- 2025-01-16 MX MX2025000642A patent/MX2025000642A/es unknown
- 2025-01-31 CO CONC2025/0001184A patent/CO2025001184A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4558507A1 (en) | 2025-05-28 |
| CA3261063A1 (en) | 2024-01-25 |
| CN119585284A (zh) | 2025-03-07 |
| IL316706A (en) | 2024-12-01 |
| WO2024017859A1 (en) | 2024-01-25 |
| TWI860785B (zh) | 2024-11-01 |
| PE20250850A1 (es) | 2025-03-21 |
| JP2025525565A (ja) | 2025-08-05 |
| CL2025000081A1 (es) | 2025-03-28 |
| US20250268894A1 (en) | 2025-08-28 |
| TW202413378A (zh) | 2024-04-01 |
| KR20250034953A (ko) | 2025-03-11 |
| AU2023311244A1 (en) | 2024-11-14 |
| MX2025000642A (es) | 2025-03-07 |
| EP4558507B1 (en) | 2026-04-29 |
| MA71551A (fr) | 2025-05-30 |
| CO2025001184A2 (es) | 2025-02-13 |
| CR20250017A (es) | 2025-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR129934A1 (es) | Compuestos macrocíclicos para el tratamiento de cáncer | |
| PE20241063A1 (es) | Composiciones y metodos para la inhibicion de ras | |
| MX2021014096A (es) | Compuestos heterociclicos, metodos de preparacion y usos de estos. | |
| MX2021004624A (es) | Derivados de 2-(2-acriloil-2,6-diazaspiro[3.4]octan-6-il)-6-(1h-in dazol-4-il)-benzonitrilo y compuestos relacionados como inhibidores de la proteina kras mutante g12c para inhibir metastasis de tumor. | |
| ES2558777T3 (es) | (R)-(E)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1H-indazol-3-il)vinil)-1H-pirazol-1-il)etanol cristalino y su uso como inhibidor de FGFR | |
| AR126854A1 (es) | Compuestos macrocíclicos para el tratamiento de cáncer | |
| ES2898385T3 (es) | Compuestos bicíclicos útiles para el tratamiento de enfermedades causadas por retrovirus | |
| AR112797A1 (es) | Inhibidores de kras g12c y métodos para utilizarlos | |
| MX2023004802A (es) | Compuestos espiro heterocíclicos y métodos de uso. | |
| MX2020011907A (es) | Inhibidores de kras g12c para el tratamiento de cancer. | |
| AR111241A1 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak | |
| EA201891463A1 (ru) | ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИН-4-ИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ (JAK) | |
| DE602004024988D1 (de) | 2-aminopyrimidin-derivate als raf-kinase-hemmer | |
| ATE512957T1 (de) | Hemmer der akt aktivität | |
| ATE446752T1 (de) | Hemmer der akt aktivität | |
| EA201890650A1 (ru) | ПРОИЗВОДНЫЕ 8-[6-[3-(АМИНО)ПРОПОКСИ]-3-ПИРИДИЛ]-1-ИЗОПРОПИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА В КАЧЕСТВЕ СЕЛЕКТИВНЫХ МОДУЛЯТОРОВ КИНАЗЫ МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ (ATM) ДЛЯ ЛЕЧЕНИЯ РАКА | |
| RU2007123360A (ru) | Пирролопиразины и пиразолопиразины, полезные в качестве ингибиторов протеинкиназ | |
| CY1107148T1 (el) | Παραγωγα ινδαζολης και φαρμακευτικες συνθεσεις για αναστολη των κινασων πρωτεϊνης και μεθοδοι για τη χρηση τους | |
| EA201991884A3 (ru) | Ингибиторы g12c kras | |
| AR040390A1 (es) | Inhibidores de quinasas de tirosina | |
| EP2205088A4 (en) | NAPHTHALIN-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | |
| AR128267A1 (es) | Derivados de azaindol y su uso como inhibidores de la erk-quinasa | |
| AR125907A1 (es) | Nueva piridina sustituida | |
| PH12022551858A1 (en) | Novel heterocyclic compounds useful as aurora a selective inhibitors | |
| AR113887A1 (es) | Derivados de indol macrocíclicos sustituidos con cloro |